ROCKVILLE, Md.--Celera Genomics here said it has entered a five-year deal to provide a subscription to its database products and early access to new genomic information to Novartis Pharma. Through the subscription, which includes access to associated bioinformatics tools for viewing, browsing, and analyzing genomics information, Novartis will gain access to Celera's human gene index, its Drosophila genome database, and its human genome database. Celera has also licensed its database products to Pharmacia and Upjohn and Amgen. Terms of the deals have not been announced.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

You may already have institutional access!

Check if I qualify.

Already a GenomeWeb or 360Dx Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

Researchers describe a way to share data while keeping it secure, Agence France Presse reports.

India's Council of Scientific and Industrial Research has a new director-general, according to ScienceInsider.

A new study links more than a hundred genes to autism spectrum disorder, Discover's D-brief blog reports.

In Science this week: genetic mutations typically associated with esophageal cancer are common in older, healthy individuals, and more.

Nov
05
Sponsored by
Sophia Genetics

With the Next Generation Sequencing (NGS), genomes sequencing has been democratized over the last decades with the detection of genomic alterations, thus replacing Sanger sequencing.